PK/PD of Digoxin in Infants With SVHD

Recruiting Phase 1 Phase 2 Interventional Study
Single-ventricle Infant Conditions Infant, Newborn, Diseases Infant, Premature, Diseases
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 Days – 6 Months
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
Duke University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The primary participant will be an infant with single ventricle heart disease. This is a research study to learn more about how the medication digoxin, which is routinely prescribed to infants and children with heart disease in pediatric cardiac intensive care units is processed by their bodies and how it may help their cardiac function. The investigators will collect blood or will collect blood…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of single ventricle congenital heart disease 2. Status post-surgical or hybrid stage 1 palliation but prior to surgical stage 2 palliation 3. Age ≤ 30 days of life at time of stage 1 palliation 4. Age \< 6 months at time of enrollment 5. Require treatment with enter…
Contacts

Alex Hammett, BS/BA

919-668-8432

Alex.Hammett@duke.edu

CONTACT